173 related articles for article (PubMed ID: 36499357)
21. Existence of Replication-Competent Minor Variants with Different Coreceptor Usage in Plasma from HIV-1-Infected Individuals.
Maeda Y; Takemura T; Chikata T; Kuwata T; Terasawa H; Fujimoto R; Kuse N; Akahoshi T; Murakoshi H; Tran GV; Zhang Y; Pham CH; Pham AHQ; Monde K; Sawa T; Matsushita S; Nguyen TV; Nguyen KV; Hasebe F; Yamashiro T; Takiguchi M
J Virol; 2020 Jun; 94(12):. PubMed ID: 32295903
[TBL] [Abstract][Full Text] [Related]
22. Microtiter plate-based antibody-competition assay to determine binding affinities and plasma/blood stability of CXCR4 ligands.
Harms M; Gilg A; Ständker L; Beer AJ; Mayer B; Rasche V; Gruber CW; Münch J
Sci Rep; 2020 Sep; 10(1):16036. PubMed ID: 32994431
[TBL] [Abstract][Full Text] [Related]
23. Complex determinants in human immunodeficiency virus type 1 envelope gp120 mediate CXCR4-dependent infection of macrophages.
Ghaffari G; Tuttle DL; Briggs D; Burkhardt BR; Bhatt D; Andiman WA; Sleasman JW; Goodenow MM
J Virol; 2005 Nov; 79(21):13250-61. PubMed ID: 16227248
[TBL] [Abstract][Full Text] [Related]
24. Covalent Binding Mechanism of Furmonertinib and Osimertinib With Human Serum Albumin.
Wu Y; Chen L; Chen J; Xue H; He Q; Zhong D; Diao X
Drug Metab Dispos; 2023 Jan; 51(1):8-16. PubMed ID: 36328480
[TBL] [Abstract][Full Text] [Related]
25. [Development of selective antagonists against an HIV second receptor].
Tamamura H
Yakugaku Zasshi; 2001 Nov; 121(11):781-92. PubMed ID: 11725546
[TBL] [Abstract][Full Text] [Related]
26. X4 HIV-1 induces neuroblastoma cell death by interference with CXCL12/CXCR4 interaction.
Hatse S; Bridger G; de Clercq E; Schols D
Cell Mol Biol (Noisy-le-grand); 2003; 49 Online Pub():OL443-52. PubMed ID: 14995074
[TBL] [Abstract][Full Text] [Related]
27. Characterization of HIV-1 entry inhibitors with broad activity against R5 and X4 viral strains.
Sironi F; Malnati M; Mongelli N; Cozzi P; Guzzo C; Ghezzi S; Martínez-Romero C; García-Sastre A; Lusso P; Jabes D; Biswas P
J Transl Med; 2015 Apr; 13():107. PubMed ID: 25888743
[TBL] [Abstract][Full Text] [Related]
28. Preparation and characterization of albumin conjugates of a truncated peptide YY analogue for half-life extension.
Ehrlich GK; Michel H; Truitt T; Riboulet W; Pop-Damkov P; Goelzer P; Hainzl D; Qureshi F; Lueckel B; Danho W; Conde-Knape K; Konkar A
Bioconjug Chem; 2013 Dec; 24(12):2015-24. PubMed ID: 24251972
[TBL] [Abstract][Full Text] [Related]
29. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog.
Jetté L; Léger R; Thibaudeau K; Benquet C; Robitaille M; Pellerin I; Paradis V; van Wyk P; Pham K; Bridon DP
Endocrinology; 2005 Jul; 146(7):3052-8. PubMed ID: 15817669
[TBL] [Abstract][Full Text] [Related]
30. Distinct molecular pathways to X4 tropism for a V3-truncated human immunodeficiency virus type 1 lead to differential coreceptor interactions and sensitivity to a CXCR4 antagonist.
Del Prete GQ; Leslie GJ; Haggarty B; Jordan AP; Romano J; Hoxie JA
J Virol; 2010 Sep; 84(17):8777-89. PubMed ID: 20573813
[TBL] [Abstract][Full Text] [Related]
31. Blockade of X4-tropic HIV-1 cellular entry by GSK812397, a potent noncompetitive CXCR4 receptor antagonist.
Jenkinson S; Thomson M; McCoy D; Edelstein M; Danehower S; Lawrence W; Wheelan P; Spaltenstein A; Gudmundsson K
Antimicrob Agents Chemother; 2010 Feb; 54(2):817-24. PubMed ID: 19949058
[TBL] [Abstract][Full Text] [Related]
32. Novel compounds containing multiple guanide groups that bind the HIV coreceptor CXCR4.
Wilkinson RA; Pincus SH; Shepard JB; Walton SK; Bergin EP; Labib M; Teintze M
Antimicrob Agents Chemother; 2011 Jan; 55(1):255-63. PubMed ID: 20937786
[TBL] [Abstract][Full Text] [Related]
33. X4 Human immunodeficiency virus type 1 gp120 promotes human hepatic stellate cell activation and collagen I expression through interactions with CXCR4.
Hong F; Saiman Y; Si C; Mosoian A; Bansal MB
PLoS One; 2012; 7(3):e33659. PubMed ID: 22479424
[TBL] [Abstract][Full Text] [Related]
34. Marked increase in anti-HIV activity, as well as inhibitory activity against HIV entry mediated by CXCR4, linked to enhancement of the binding ability of tachyplesin analogs to CXCR4.
Xu Y; Tamamura H; Arakaki R; Nakashima H; Zhang X; Fujii N; Uchiyama T; Hattori T
AIDS Res Hum Retroviruses; 1999 Mar; 15(5):419-27. PubMed ID: 10195751
[TBL] [Abstract][Full Text] [Related]
35. HIV-1 chemokine coreceptor utilization in paired cerebrospinal fluid and plasma samples: a survey of subjects with viremia.
Spudich SS; Huang W; Nilsson AC; Petropoulos CJ; Liegler TJ; Whitcomb JM; Price RW
J Infect Dis; 2005 Mar; 191(6):890-8. PubMed ID: 15717264
[TBL] [Abstract][Full Text] [Related]
36. Mutations That Increase the Stability of the Postfusion gp41 Conformation of the HIV-1 Envelope Glycoprotein Are Selected by both an X4 and R5 HIV-1 Virus To Escape Fusion Inhibitors Corresponding to Heptad Repeat 1 of gp41, but the gp120 Adaptive Mutations Differ between the Two Viruses.
Zhuang M; Vassell R; Yuan C; Keller PW; Ling H; Wang W; Weiss CD
J Virol; 2019 Jun; 93(11):. PubMed ID: 30894471
[TBL] [Abstract][Full Text] [Related]
37. Absolute quantitation of NAPQI-modified rat serum albumin by LC-MS/MS: monitoring acetaminophen covalent binding in vivo.
LeBlanc A; Shiao TC; Roy R; Sleno L
Chem Res Toxicol; 2014 Sep; 27(9):1632-9. PubMed ID: 25168029
[TBL] [Abstract][Full Text] [Related]
38. Shift of clinical human immunodeficiency virus type 1 isolates from X4 to R5 and prevention of emergence of the syncytium-inducing phenotype by blockade of CXCR4.
Esté JA; Cabrera C; Blanco J; Gutierrez A; Bridger G; Henson G; Clotet B; Schols D; De Clercq E
J Virol; 1999 Jul; 73(7):5577-85. PubMed ID: 10364306
[TBL] [Abstract][Full Text] [Related]
39. Positive regulation of CXCR4 expression and signaling by interleukin-7 in CD4+ mature thymocytes correlates with their capacity to favor human immunodeficiency X4 virus replication.
Schmitt N; Chêne L; Boutolleau D; Nugeyre MT; Guillemard E; Versmisse P; Jacquemot C; Barré-Sinoussi F; Israël N
J Virol; 2003 May; 77(10):5784-93. PubMed ID: 12719571
[TBL] [Abstract][Full Text] [Related]
40. Interleukin-4-transgenic hu-PBL-SCID mice: a model for the screening of antiviral drugs and immunotherapeutic agents against X4 HIV-1 viruses.
Okuma K; Tanaka R; Ogura T; Ito M; Kumakura S; Yanaka M; Nishizawa M; Sugiura W; Yamamoto N; Tanaka Y
J Infect Dis; 2008 Jan; 197(1):134-41. PubMed ID: 18171296
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
